Lan Luo, MD
Cardiovascular Disease · Ocala, FLNPI 1295938975
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,669 of the $11,258 with a category attached, or 77.0%. It is spread thinly across 41 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,489 and has fallen 56.6% since, to $1,081 in 2025.
Across 462 payments — averaging $24.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Astrazeneca UK Limited$1K
- Amgen$893
- AstraZeneca$740
- Johnson & Johnson$620
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$545
- plus $5K from 35 others
Across 242 payments — averaging $11,199 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$791K
- Eli Lilly$754K
- AstraZeneca$356K
- Boehringer Ingelheim International GmbH$210K
- Novartis$191K
- Boehringer Ingelheim Pharma GmbH & Co.kg$95K
- plus $313K from 7 others
What the payments were for
- Consulting fees$2,56823%
- Food & beverage$8,66977%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,258 in reported general payments places this provider in the 80th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,411 | $1,408,747 |
| XareltoRivaroxaban | 715 | $706,744 |
| EntrestoSacubitril/Valsartan | 591 | $701,889 |
| FarxigaDapagliflozin Propanediol | 461 | $425,159 |
| Repatha SureclickEvolocumab | 477 | $385,750 |
| VyndamaxTafamidis | 12 | $272,673 |
| JardianceEmpagliflozin | 279 | $267,642 |
| OzempicSemaglutide | 154 | $164,099 |
| MultaqDronedarone Hcl | 100 | $141,995 |
| MounjaroTirzepatide | 99 | $114,185 |
| BrilintaTicagrelor | 136 | $98,304 |
| NexletolBempedoic Acid | 103 | $63,351 |
| NexlizetBempedoic Acid/Ezetimibe | 99 | $59,358 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 178 | $35,108 |
| VerquvoVericiguat | 34 | $33,399 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Vyndamax | $497 | $1,681,4211,423 claims |
| Johnson & JohnsonXarelto | $620 | $706,744715 claims |
| NovartisEntresto | $2,044 | $701,889591 claims |
| AstraZenecaFarxiga, Brilinta | $740 | $523,463597 claims |
| Boehringer IngelheimJardiance | $436 | $267,642279 claims |
| Novo NordiskOzempic | $153 | $164,099154 claims |
| Sanofi-aventis U.S. LLCMultaq | $305 | $141,995100 claims |
| Esperion Therapeutics, Inc.Nexletol, Nexlizet | $536 | $122,709202 claims |
| MerckVerquvo | $456 | $33,39934 claims |
| AmgenCorlanor | $893 | $12,54517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Ocala
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
- Neel PatelMaitland$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.